ArticleBMC public health2025
Changes in the monitoring and management of hypertension during the COVID-19 pandemic.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic caused major healthcare disruptions including the diagnosis and management of hypertension. We evaluated the impact of the COVID-19 pandemic on the monitoring and management of hypertension within the US. Military Health System (MHS) and assessed differences in screening across racial groups and socioeconomic strata.
methodsRetrospective evaluation of MHS beneficiaries aged 18-64 years. We compared the hypertension incidence, frequency of blood pressure (BP) monitoring and proportion of hypertension cases with adequately controlled BP during the last healthcare encounter from September 1, 2017-February 28, 2020 (pre-COVID-19 period) to the time frame of the COVID-19 period (March 1, 2020-September 30, 2022).
findingsWe identified 440,107 new hypertension cases among 4,825,679 TRICARE beneficiaries (7.63%, n = 317,976 in the pre-COVID-19 period to 3.25%, n = 122,131, during the COVID-19 period (p < 0.001). Following adjusted analysis, beneficiaries who identified as Black (OR 1.53, 95% CI 1.51-1.55), American Indian/Alaskan Native (OR 1.12, 95% CI 1.05-1.19), or Asian/Pacific Islander (OR 1.15, 95% CI 1.12-1.18), and Senior Enlisted personnel (OR 1.34, 95% CI 1.31-1.37) were more likely to receive a diagnosis of hypertension over the five-year study period. The median number of BP measurements (8 vs. 4) and the percentage of hypertension cases on anti-hypertensive medications (5.7% vs. 3.7%) significantly decreased during the COVID-19 period (p < 0.001).
interpretationWe found a significant reduction in the diagnosis of hypertension among beneficiaries during the COVID-19 period. BP control decreased in parallel during the period of COVID-19, with a corresponding reduction in follow-up health care visits among individuals with uncontrolled hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.